Abstract
Genetic testing should be offered to all women less than 40 years of age who are diagnosed with breast cancer, and patients with PABC are generally among them. However, there is no specific study about these cases, and whether genetic testing should be carried out during or after pregnancy is not known. Generally, testing before delivery should only be performed if positive results change management plans, such as undergoing fetal testing and choosing mastectomy instead of breast conserving surgery.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM et al (2019) Consensus guidelines on genetictesting for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol 26(10):3025–3031
Lynch JA, Venne V, Berse B (2015) Genetic tests to identify risk for breast cancer. Semin Oncol Nurs 31(2):100–107
Moyer VA (2014) Force USPST. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 160(4):271–281
Bevers TB, Helvie M, Bonaccio E, Calhoun KE, Daly MB, Farrar WB et al (2018) Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 16(11):1362–1389
Gage M, Wattendorf D, Henry LR (2012) Translational advances regarding hereditary breast cancer syndromes. J Surg Oncol 105(5):444–451
Campeau PM, Foulkes WD, Tischkowitz MD (2008) Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet 124(1):31–42
Lalloo F, Varley J, Ellis D, Moran A, O’Dair L, Pharoah P et al (2003) Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 361(9363):1101–1102
Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ et al (2009) Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27(8):1250–1256
Schon K, Tischkowitz M (2018) Clinical implications of germline mutations in breast cancer: TP53. Breast Cancer Res Treat 167(2):417–423
Elezaby M, Lees B, Maturen KE, Barroilhet L, Wisinski KB, Schrager S, Wilke LG, Sadowski E (2019 Apr 30) BRCA mutation carriers: breast and ovarian cancer screening guidelines and imaging considerations. Radiology 291(3):554–569
Warner E (2018) Screening BRCA1 and BRCA2 mutation carriers for breast cancer. Cancers 10(12):477
Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA (2018) Breast cancer screening in women at higher-than-average risk: recommendations from the ACR. J Am Coll Radiol 15(3):408–414
Carmichael H, Matsen C, Freer P, Kohlmann W, Stein M, Buys SS et al (2017) Breast cancer screening of pregnant and breastfeeding women with BRCA mutations. Breast Cancer Res Treat 162(2):225–230
Clancy T (2010) A clinical perspective on ethical arguments around prenatal diagnosis and preimplantation genetic diagnosis for later onset inherited cancer predispositions. Familial Cancer 9(1):9–14
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Chen, J., Prasath, V., Axilbund, J., Habibi, M. (2020). Concerns of Hereditary Breast Cancer in Pregnancy and Lactation. In: Alipour, S., Omranipour, R. (eds) Diseases of the Breast during Pregnancy and Lactation. Advances in Experimental Medicine and Biology, vol 1252. Springer, Cham. https://doi.org/10.1007/978-3-030-41596-9_17
Download citation
DOI: https://doi.org/10.1007/978-3-030-41596-9_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-41595-2
Online ISBN: 978-3-030-41596-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)